On Nov 20, major Wall Street analysts update their ratings for $Medtronic (MDT.US)$, with price targets ranging from $90 to $105.
Morgan Stanley analyst Patrick Wood maintains with a buy rating, and maintains the target price at $98.
BofA Securities analyst Travis Steed maintains with a buy rating, and sets the target price at $100.
Citi analyst Joanne Wuensch maintains with a hold rating, and maintains the target price at $92.
Barclays analyst Matt Miksic maintains with a buy rating, and maintains the target price at $105.
UBS analyst Danielle Antalffy maintains with a hold rating, and adjusts the target price from $90 to $93.
Furthermore, according to the comprehensive report, the opinions of $Medtronic (MDT.US)$'s main analysts recently are as follows:
Although maintaining a positive outlook for the FY25 high single-digit EPS growth rate as an indicator for future performance, analysts note the company will face challenges into FY26 with ongoing FX pressures, dilutive effects from new products and capital rollouts, and slight tax headwinds, which may impede a steady return to high single-digit EPS growth.
Medtronic's Q2 revenue outperformed expectations largely due to strong performance in the cardiovascular, neuro, and diabetes sectors. Furthermore, the company has increased its FY25 growth projections to between 4.75%-5.0%. Analysts maintain a positive outlook into FY26, anticipating that earnings growth may surpass overall revenue growth.
Here are the latest investment ratings and price targets for $Medtronic (MDT.US)$ from 11 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月20日，多家华尔街大行更新了$美敦力 (MDT.US)$的评级，目标价介于90美元至105美元。
摩根士丹利分析师Patrick Wood维持买入评级，维持目标价98美元。
美银证券分析师Travis Steed维持买入评级，目标价100美元。
花旗分析师Joanne Wuensch维持持有评级，维持目标价92美元。
巴克莱银行分析师Matt Miksic维持买入评级，维持目标价105美元。
瑞士银行分析师Danielle Antalffy维持持有评级，并将目标价从90美元上调至93美元。
此外，综合报道，$美敦力 (MDT.US)$近期主要分析师观点如下：
尽管对FY25高单位数每股收益增长率保持积极展望，以此作为未来业绩的指标，但分析师指出，由于持续的外汇压力、新产品和资本的推出所带来的稀释效应，以及轻微的税收阻力，公司在FY26将面临挑战，这可能会阻碍稳步返回高单位数的每股收益增长。
美敦力第二季度营业收入超出预期，主要得益于心血管、神经和糖尿病领域的强劲表现。此外，公司已将FY25的增长预期提高至4.75%-5.0%之间。分析师对FY26保持乐观展望，预计盈利增长可能会超过整体营业收入的增长。
以下为今日11位分析师对$美敦力 (MDT.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
